Every Hemophilia A Product and Their Death and Adverse Reactions Data

Below you will find a current list of Hemophilia A products along with their death and adverse reactions data.


By looking at this data, emicizumab (Hemlibra) has the most negative data in such a short period of time since FDA approval.



BRAND

DEATHS

ADVERSE REACTIONS

FDA APPROVAL


HEMLIBRA

54

700

OCTOBER 2018


ADVATE

133

2,572

DECEMBER 2011


ADYNOVATE

15

280

NOVEMBER 2015


AFSTYLA

2

46

MAY 2016


ELOCTATE

23

488

JUNE 2014


ESPEROCT

1

6

FEBRUARY 2019


JIVI

1

50

AUGUST 2018


KOGENATE

46

1,316

MARCH 2009


KOVALTRY

15

197

MARCH 2016


NOVOEIGHT

15

89

OCTOBER 2013


NUWIQ

2

21

SEPTEMBER 2015


RECOMBINATE

27

481

UNKNOWN


XYNTHA

28

355

FEBRUARY 2008

0 comments

Recent Posts

See All